E-LIB Suche - Ergebnisse für: Zinzani P. L

1

Phase 1 trial of EO2463 peptide‐based immunotherapy as mono..:

Pinto, A. A. ; Bosch, F. ; Bisneto, J. C. Villasboas...
Hematological Oncology. 41 (2023) S2 - p. 581-582 , 2023

Link: https://doi.org/10.1002/..

2

LACUTAMAB IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES (MF):..:

Kim, Y. H. ; Bagot, M. ; Ortiz‐Romero, P. L....
Hematological Oncology. 41 (2023) S2 - p. 196-197 , 2023

Link: https://doi.org/10.1002/..

3

EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PH..:

Frustaci, A. M. ; Montillo, M. ; Rossi, D....
Hematological Oncology. 41 (2023) S2 - p. 62-63 , 2023

Link: https://doi.org/10.1002/..

4

MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VE..:

Sehn, L. ; Sarkozy, C. ; Song, Y....
Hematological Oncology. 41 (2023) S2 - p. 168-170 , 2023

Link: https://doi.org/10.1002/..

5

The treatment of Burkitt lymphoma with the Berlin‐Frankfurt..:

Broccoli, A. ; Argnani, L. ; Gugliotta, G....
Hematological Oncology. 41 (2023) S2 - p. 427-427 , 2023

Link: https://doi.org/10.1002/..

6

Long‐term efficacy and safety of zanubrutinib (ZANU) in rel..:

Trotman, J. ; Tedeschi, A. ; Hu, B....
Hematological Oncology. 41 (2023) S2 - p. 390-392 , 2023

Link: https://doi.org/10.1002/..

7

LONG‐TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RE..:

Caimi, P. F ; Ai, W. Z ; Alderuccio, J. P....
Hematological Oncology. 41 (2023) S2 - p. 209-212 , 2023

Link: https://doi.org/10.1002/..

8

The Italian CART‐SIE real life multicenter observational st..:

Chiappella, A. ; Dodero, A. ; Ljevar, S....
Hematological Oncology. 41 (2023) S2 - p. 519-520 , 2023

Link: https://doi.org/10.1002/..

9

PILOT PHASE II STUDY OF SELINEXOR IN COMBINATION WITH IFOSF..:

Chiappella, A. ; Dodero, A. ; Carniti, C....
Hematological Oncology. 41 (2023) S2 - p. 845-846 , 2023

Link: https://doi.org/10.1002/..

10

Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life..:

Iannitto, E. ; Balzarotti, M. ; Martelli, M....
Hematological Oncology. 41 (2023) S2 - p. 408-410 , 2023

Link: https://doi.org/10.1002/..

11

Predicting ICANS by means of plasma CAR‐T cell derived extr..:

De Felice, F. ; Storci, G. ; Ricci, F....
Hematological Oncology. 41 (2023) S2 - p. 534-534 , 2023

Link: https://doi.org/10.1002/..

12

Encouraging complete responses (CRs) with CDK9 inhibitor AZ..:

Zinzani, P. L. ; Feldman, T. ; Collins, G....
Hematological Oncology. 41 (2023) S2 - p. 568-569 , 2023

Link: https://doi.org/10.1002/..

13

Single‐agent rituximab as an effective salvage therapy in p..:

Broccoli, A. ; Argnani, L. ; Nanni, L....
Hematological Oncology. 41 (2023) S2 - p. 397-397 , 2023

Link: https://doi.org/10.1002/..

14

Duvelisib in patients with relapsed/refractory peripheral T..:

Mehta‐Shah, N. ; Jacobsen, E. D. ; Zinzani, P. L....
Hematological Oncology. 41 (2023) S2 - p. 499-500 , 2023

Link: https://doi.org/10.1002/..

15

CART‐SIE REAL LIFE STUDY: PRIMARY MEDIASTINAL B‐CELL LYMPHO..:

Chiappella, A. ; Dodero, A. ; Guidetti, A....
Hematological Oncology. 41 (2023) S2 - p. 198-199 , 2023

Link: https://doi.org/10.1002/..